Journal
CIRCULATION
Volume 140, Issue 14, Pages 1205-1216Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.119.040551
Keywords
cardiovascular diseases; heart failure; mitochondria
Funding
- National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)
- NIH [R01GM086688, R01DK103750, 1UL1TR001430, R01DK098646, R01DK100826, RO1HL064750, NO1HV-28178, R35HL135736, R01HL128071, R01HL124116, P01HL112730, R01HL132075, R01HL144509, R01HL128349, R01HL058493, R01HL136496, R01HL52141]
- American Heart Association [16GRNT27660006, 16GRNT30990018, R01HL134821, R21HL126209, P01HL092969, R01HL126952, R01HL133003-01A1, R01GM113816-01, R01HL122124, R01HL093671, R01HL137426, R01HL142864]
- Harrington Discovery Institute [R01HL137266, R01HL110349, R01HL129510, R01HL126209, R01HL142628, R01HL137259, R01HL125695, R01NS021328, R01MH108592, R01OD010944, R01HL61912, R01HL63030]
- Hemophilia Center of Western Pennsylvania
- US Department of Defense [W81XWH-16-1-0401]
Ask authors/readers for more resources
Mitochondria have emerged as a central factor in the pathogenesis and progression of heart failure, and other cardiovascular diseases, as well, but no therapies are available to treat mitochondrial dysfunction. The National Heart, Lung, and Blood Institute convened a group of leading experts in heart failure, cardiovascular diseases, and mitochondria research in August 2018. These experts reviewed the current state of science and identified key gaps and opportunities in basic, translational, and clinical research focusing on the potential of mitochondria-based therapeutic strategies in heart failure. The workshop provided short- and long-term recommendations for moving the field toward clinical strategies for the prevention and treatment of heart failure and cardiovascular diseases by using mitochondria-based approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available